Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease

INTRODUCTION: Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic plaque burden reduction did not result in clinical benefit. Lan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmer, Jennifer A., Shcherbinin, Sergey, Devous, Michael D., Bragg, Sonja M., Selzler, Katherine J., Wessels, Alette M., Shering, Craig, Mullen, Jamie, Landry, John, Andersen, Scott W., Downing, AnnCatherine M., Fleisher, Adam S., Svaldi, Diana Otero, Sims, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882543/
https://www.ncbi.nlm.nih.gov/pubmed/33614894
http://dx.doi.org/10.1002/trc2.12123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882543/
https://www.ncbi.nlm.nih.gov/pubmed/33614894
http://dx.doi.org/10.1002/trc2.12123

Ejemplares similares